MarginsXMarginsX
Home › Markets › Health Care › HIND

Vyome Holdings Inc. (HIND)

HIND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.53
-3.16% on the day
Market cap
$10.7M
Nano cap
Revenue · 2025
$320K
+24.4% on 2024
Net income · 2025
-$10.3M
-3209.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/0001213900-26-029500-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHIND on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2016
SEC CIK0001427570
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$320K
Net income-$10.3M
Operating income-$10.5M
Net margin-3209.7%
Operating margin-3269.4%
Revenue growth+24.4%
Cash$5.0M
Total assets$6.5M
P/E (computed)Net income was not positive
P/S (computed)33.6×

Warning signs

Cash runway
18.6 months
$7.0M cash at September 30, 2026
Share count, 1 year
+24.3%
2025-11-13 to 2026-11-09 · +309804.7% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$7.0M cash; operating cash flow -$1.1M a quarter.Report 2026-09-30
Shares outstanding7,018,528 (2026-11-09); 5,644,494 a year earlier; 13,135,478 three years earlier. 3y figure adjusted for splits (1-for-5800 overall).Cover page 2026-11-09
Reverse splits, 3 years3; latest 1-for-4 on 2025-08-15Source 2025-08-15
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKreit & Chiu CPA LLP, Los Angeles, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-08-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$58K-$885K-$628K$7.0MNo debt tags$153K10-Q 2026-11-12
Q2 2026
2026-06-30
$27K-$686K-$904K$7.9MNo debt tags$130K10-Q 2026-08-12
Q1 2026
2026-03-31
$32K-$963K-$1.4M$8.8MNo debt tags$153K10-Q 2026-05-12
Q4 2025
2025-12-31
$37K-$1.2M-$1.5M$5.0MNo debt tags$320K10-K 2026-03-18
Q3 2025
2025-09-30
$35K-$8.4M-$1.7M$5.7MNo debt tags$345K10-Q 2026-11-12
Q2 2025
2025-06-30
$50K-$309K-$306K$4.1MNo debt tags$394K10-Q 2026-08-12
Q1 2025
2025-03-31
$199K-$294K-$204K$2.5MNo debt tags$2.3M10-Q 2026-05-12
Q4 2024
2024-12-31
$61K-$307K-$3K$102K$811K$4.1M10-K 2026-03-18

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32025-11-26
Latest annual report
ANNUAL REPORT
10-K2026-03-18
Latest quarterly / interim
QUARTERLY REPORT
10-Q2026-11-12
Latest current report
CURRENT REPORT
8-K2026-08-28
Latest proxy
PROXY STATEMENT
DEF 14A2026-03-31

Source: SEC EDGAR submissions feed, 694 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week0.0%
1 month-19.8%
3 months-26.9%
Year to date-54.1%
1 year-68.0%
From 52-week high-72.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PTNPalatin Technologies Inc.$6.13-1.69%$10.9M
RADXRadiopharm Theranostics Limited$0.7676+1.00%$11.1M
BFRIBiofrontera Inc.$0.5700-18.58%$10.2M
ASBPAspire-Lakewood Holdings Inc.$8.06-5.29%$11.3M
CLRBCellectar Biosciences Inc.$1.01-11.40%$10.1M
AEONAEON Biopharma Inc.$0.1407-8.04%$10.1M
DAREDare Bioscience Inc.$0.5842-11.13%$11.5M
BIVIBioVie Inc.$1.08-4.42%$11.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier